• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

D1多巴胺受体药效基团的进一步定义:反式-6,6a,7,8,9,13b-六氢-5H-苯并[d]萘并[2,1-b]氮杂卓作为β-苯基多巴胺刚性类似物的合成。

Further definition of the D1 dopamine receptor pharmacophore: synthesis of trans-6,6a,7,8,9,13b-hexahydro-5H-benzo[d]naphth[2,1-b]azepines as rigid analogues of beta-phenyldopamine.

作者信息

Negash K, Nichols D E, Watts V J, Mailman R B

机构信息

Department of Medicinal Chemistry and Molecular Pharmacology, School of Pharmacy and Pharmacal Sciences, Purdue University, West Lafayette, Indiana 47907, USA.

出版信息

J Med Chem. 1997 Jul 4;40(14):2140-7. doi: 10.1021/jm970157a.

DOI:10.1021/jm970157a
PMID:9216832
Abstract

In an effort to define further the active geometry of the beta-phenyldopamine pharmacophore of certain dopamine D1 agonists, the title compounds have been synthesized as conformationally restricted homologues of the potent benzophenanthridine dopamine D1 agonist dihydrexidine 4a. The dihydroxy secondary amine 5b was evaluated as a potential agonist, whereas the N-methyl compounds 5a and 5c were hypothesized to be antagonists. Surprisingly, none of the three compounds had high affinity for dopamine D1 or D2 receptors. A comparison of the low-energy conformations of these molecules shows that the pendant phenyl ring of 5b is twisted about 28 degrees relative to that of the corresponding ring of 4a. Further, the additional methylene used to expand the C ring of 5b projects toward the alpha face of the molecule, perhaps suggesting that steric protrusion in this region of the molecule is not tolerated. Finally, the phenethylamine fragment incorporated into these molecules deviates about 30 degrees from the antiperiplanar conformation postulated to be necessary for agonist activity. On the other hand, the potential antagonist molecules 5a and 5c were compared with the dopamine D1 antagonist SCH 39166 2. The conformations of the former two structures differ quite dramatically from that of 2. The most notable differences lie in the relative orientations of the pendant phenyl rings in the two series, as well as the fact that the ethylamine fragment in 2 approximates a gauche conformation, while the comparable orientation in 5a and 5c more nearly approaches an antiperiplanar conformation. These findings will be used to refine further the model of the dopamine D1 agonist receptor that we have previously developed.

摘要

为了进一步明确某些多巴胺D1激动剂的β-苯基多巴胺药效基团的活性几何结构,已合成了标题化合物,作为强效苯并菲啶多巴胺D1激动剂二氢瑞香素4a的构象受限类似物。对二羟基仲胺5b作为潜在激动剂进行了评估,而N-甲基化合物5a和5c被推测为拮抗剂。令人惊讶的是,这三种化合物对多巴胺D1或D2受体均无高亲和力。对这些分子的低能构象进行比较表明,5b的侧链苯环比4a相应环扭转了约28度。此外,用于扩展5b的C环的额外亚甲基朝向分子的α面突出,这可能表明该分子区域的空间突出是不被允许的。最后,引入这些分子中的苯乙胺片段与推测的激动剂活性所需的反式共平面构象偏离约30度。另一方面,将潜在拮抗剂分子5a和5c与多巴胺D1拮抗剂SCH 39166 2进行了比较。前两种结构的构象与2的构象有很大差异。最显著的差异在于两个系列中侧链苯环的相对取向,以及2中的乙胺片段接近 gauche 构象,而5a和5c中的类似取向更接近反式共平面构象。这些发现将用于进一步完善我们之前建立的多巴胺D1激动剂受体模型。

相似文献

1
Further definition of the D1 dopamine receptor pharmacophore: synthesis of trans-6,6a,7,8,9,13b-hexahydro-5H-benzo[d]naphth[2,1-b]azepines as rigid analogues of beta-phenyldopamine.D1多巴胺受体药效基团的进一步定义:反式-6,6a,7,8,9,13b-六氢-5H-苯并[d]萘并[2,1-b]氮杂卓作为β-苯基多巴胺刚性类似物的合成。
J Med Chem. 1997 Jul 4;40(14):2140-7. doi: 10.1021/jm970157a.
2
9-Dihydroxy-2,3,7,11b-tetrahydro-1H-naph[1,2,3-de]isoquinoline: a potent full dopamine D1 agonist containing a rigid-beta-phenyldopamine pharmacophore.9-二羟基-2,3,7,11b-四氢-1H-萘并[1,2,3-de]异喹啉:一种强效的多巴胺D1完全激动剂,含有刚性β-苯基多巴胺药效团。
J Med Chem. 1996 Jan 19;39(2):549-55. doi: 10.1021/jm950707+.
3
Conformational analysis of D1 dopamine receptor agonists: pharmacophore assessment and receptor mapping.D1多巴胺受体激动剂的构象分析:药效团评估与受体图谱分析
J Med Chem. 1996 Jan 5;39(1):285-96. doi: 10.1021/jm9502100.
4
CoMFA-based prediction of agonist affinities at recombinant D1 vs D2 dopamine receptors.基于比较分子力场分析(CoMFA)对重组D1和D2多巴胺受体激动剂亲和力的预测
J Med Chem. 1998 Oct 22;41(22):4385-99. doi: 10.1021/jm9800292.
5
trans-2,3-dihydroxy-6a,7,8,12b-tetrahydro-6H-chromeno[3,4-c]isoquinoline: synthesis, resolution, and preliminary pharmacological characterization of a new dopamine D1 receptor full agonist.反式-2,3-二羟基-6a,7,8,12b-四氢-6H-色烯并[3,4-c]异喹啉:一种新型多巴胺D1受体完全激动剂的合成、拆分及初步药理学特性研究
J Med Chem. 2006 Nov 16;49(23):6848-57. doi: 10.1021/jm0604979.
6
8,9-dihydroxy-1,2,3,11b-tetrahydrochromeno[4,3,2,-de]isoquinoline (dinoxyline), a high affinity and potent agonist at all dopamine receptor isoforms.8,9 - 二羟基 - 1,2,3,11b - 四氢色烯并[4,3,2 - de]异喹啉(地诺昔林),对所有多巴胺受体亚型均为高亲和力且强效的激动剂。
Bioorg Med Chem. 2004 Mar 15;12(6):1403-12. doi: 10.1016/j.bmc.2004.01.008.
7
Synthesis and dopaminergic properties of benzo-fused analogues of quinpirole and quinelorane.
J Med Chem. 1999 Mar 11;42(5):935-40. doi: 10.1021/jm9804533.
8
Analogues of doxanthrine reveal differences between the dopamine D1 receptor binding properties of chromanoisoquinolines and hexahydrobenzo[a]phenanthridines.多沙林类似物揭示了色烷异喹啉和六氢苯并[a]菲啶类化合物与多巴胺 D1 受体结合特性的差异。
Eur J Med Chem. 2012 Feb;48:97-107. doi: 10.1016/j.ejmech.2011.11.039. Epub 2011 Dec 3.
9
Evaluation of cis- and trans-9- and 11-hydroxy-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridines as structurally rigid, selective D1 dopamine receptor ligands.顺式和反式-9-和11-羟基-5,6,6a,7,8,12b-六氢苯并[a]菲啶作为结构刚性、选择性D1多巴胺受体配体的评估。
J Med Chem. 1995 Jan 20;38(2):318-27. doi: 10.1021/jm00002a013.
10
Synthesis and evaluation of 6,7-dihydroxy-2,3,4,8,9,13b-hexahydro-1H- benzo[6,7]cyclohepta[1,2,3-ef][3]benzazepine, 6,7-dihydroxy- 1,2,3,4,8,12b-hexahydroanthr[10,4a,4-cd]azepine, and 10-(aminomethyl)-9,10- dihydro-1,2-dihydroxyanthracene as conformationally restricted analogs of beta-phenyldopamine.
J Med Chem. 1995 Jun 23;38(13):2395-409. doi: 10.1021/jm00013a015.

引用本文的文献

1
Tetrahydroisoquinolines functionalized with carbamates as selective ligands of D2 dopamine receptor.用氨基甲酸酯官能化的四氢异喹啉作为D2多巴胺受体的选择性配体。
J Mol Model. 2017 Sep 2;23(9):273. doi: 10.1007/s00894-017-3441-6.